Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, elaborates on some of the key takeaways from GO30140, the multi-cohort phase I study investigating combination atezolizumab and bevacizumab in 1st line hepatocellular carcinoma (HCC)

Tags: ESMO 2019Liver (includes HCC, Billiary Tract)

Published: 11 October 2019

Recent Videos: Liver (includes HCC, Billiary Tract)

video

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, ...

video

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, ...

video

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, ...

video

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

Dr. Kaseb, GI Medical Oncology, MD Anderson Cancer Center, on whether adding bevacizumab to atezolizumab may prove more effective than ...

video

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

Dr. Kaseb, GI Medical Oncology, MD Anderson Cancer Center, elaborates on the phase 1b study investigating combination atezolizumab and bevacizumab ...

video

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

Dr. Kaseb, GI Medical Oncology, MD Anderson Cancer Center, offers opinion on whether nivolumab and ipilimumab should be combined to ...

video

Thomas A. Abrams, MD, outlines next steps if an HCC patient fails 1st line therapy with I-O

Dr. Abrams, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, outlines next steps if an hepatocellular carcinoma (HCC) patient ...

video

Richard S. Finn, MD, speculates on the next phase of HCC management and research

Dr. Finn, Director, Translational Research Laboratory, Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, ...

video

Imane El Dika, MD, outlines next steps if an HCC patient fails 1st line therapy

Dr. El Dika, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center, outlines next steps if an hepatocellular carcinoma (HCC) patient ...

video

Richard S. Finn, MD, outlines the next steps if an HCC patient fails 1st line therapy

Dr. Finn, Director, Translational Research Laboratory, Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, ...

Related Videos

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

video-image

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

video-image

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

video-image

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

video-image

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

video-image

Thomas A. Abrams, MD, outlines next steps if an HCC patient fails 1st line therapy with I-O

video-image

Richard S. Finn, MD, speculates on the next phase of HCC management and research

video-image

Imane El Dika, MD, outlines next steps if an HCC patient fails 1st line therapy

video-image

Richard S. Finn, MD, outlines the next steps if an HCC patient fails 1st line therapy

video-image

Imane El Dika, MD, considers the role of I-O in the management of HCC

video-image

Richard S. Finn, MD, offers opinion on the broader role of I-O in the management of HCC

video-image

Imane El Dika, MD, elaborates on the outcomes of Keynote-240 presented at ASCO 2019

video-image

Richard S. Finn, MD, regarding outcomes from Keynote-240 in 1st line HCC

video-image

Daneng Li, MD, elaborates on the COSMIC-312 trial in hepatocellular carcinoma

video-image

Daneng Li, MD, describes next steps if an HCC patient fails 1st line I-O therapy

video-image

Daneng Li, MD, considers the role of immuno-oncology in the management of HCC

video-image

Daneng Li, MD, tells us about the outcomes of Keynote 240 presented at ASCO 2019

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018

video-image

Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib

video-image

Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients

video-image

Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib

video-image

Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC

video-image

Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients

video-image

Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management

video-image

Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients

video-image

Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)

video-image

Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib

video-image

Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today

video-image

Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC

video-image

Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)

video-image

Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018

video-image

Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients

video-image

Jeffrey Meyerhardt, MD, offers opinion on the effectiveness of SIRT in treatment of metastatic HCC

video-image

Richard Goldberg, MD, FASCO, shares his impression of the adjuvant biliary tract study at ASCO 2017

video-image

Philip Philip, MD, on the lenvatinib data in patients with unresectable HCC presented at ASCO 2017

video-image

Philip Philip, MD, shares his impression of the capcitabine data in biliary cancers

video-image

Nevena Damjanov, MD, comments on identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on the Phase 3 Checkpoint 459 trial studying nivolumab in HCC

video-image

Nevena Damjanov, MD, shares her impressions of lenvatinib data in 1st line uHCC presented at ASCO

video-image

Nevena Damjanov, MD, discusses new agents being studied for treatment of advanced HCC

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

Robert L. Coleman, MD, FACOG, FACS, on the VELIA, PAOLA-1 and PRIMA studies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Nader Sanai, MD, shares details from the most promising studies in glioma presented at ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Ulrik Lassen, MD, PhD, discusses the incidence of TRK fusion in various tumor types

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcoma

video-image

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

video-image

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumors

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

David Gershenson, MD, tells us what's new in the treatment of rare epithelial cancers

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Brian Van Tine, MD, discusses the design of the SPEARHEAD-1 trial

video-image

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019

video-image

Christopher J. Hoimes, MD, considers the role of I-O in perioperative muscle-invasive bladder cancer

video-image

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcoma

video-image

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

video-image

Christopher J. Hoimes, MD, comments on the design and outcomes of KEYNOTE-866

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

Nader Sanai, MD, on the role of ribociclib in the management of gliomas

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC